Publications
2020
. EPI-7386, a potent N-terminal domain androgen receptor inhibitor, with a favorable preclinical safety and superior in vitro/in vivo profile, in clinical development for prostate cancer. Prostate Cancer Foundation 27th Annual Scientific Retreat.
Read More > Prostate Cancer Foundation 27th Annual Scientific Retreat Poster. Pre-clinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. ESMO Virtual Congress 2020. (Poster ID #11P).
Read More > ESMO Virtual Congress 2020 Poster. Pre-clinical development of the second-generation N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer. American Association for Cancer Research Virtual Annual Meeting II 2020. (Abstract ID #1953).
Read More > 2020 AACR Virtual Annual Meeting II Poster. The preclinical characterization and development of EPI-7386, an N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer. [Poster Session]. American Urology Association Annual Conference, Washington, DC, United States.
Read More > 2020 American Urology Association Annual Conference Poster. IND Candidate EPI-7386 as an N-terminal Domain Androgen Receptor Inhibitor in Development for the Treatment of Prostate Cancer. American Society of Clinical Oncology Genitourinary Cancers Symposium 2020. (Abstract ID #142).
Read More > 2020 Genitourinary Cancers Symposium Poster